Onco Actu du 10 avril 2020

	1.1 BIOLOGIE - GÉNOME
Science Snaps: rearranging our understanding of the cancer genome [Cancer Research UK] The next step in Sauer’s research is to understand the relationship between centrosome amplification and the rearrangement of the genome that we commonly see in cancer cells. “It’s a bit like the chicken and the egg question, which one came first?” she explains.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Research identifies critical protein in cancer treatment-related heart damage [Washington State University] The research team showed that a protein named FOXO1 plays a critical role in heart damage resulting from treatment with doxorubicin, an anthracycline chemotherapy drug. Using a rodent model, they also demonstrated that by suppressing FOXO1 through the use of FOXO1 inhibitor drugs they could prevent doxorubicin-induced heart damage.
	5.12.4 IMMUNOTHÉRAPIES - ESSAIS
Immunotherapy treatment after chemotherapy significantly slows metastatic bladder cancer [EurekAlert!] The study is the first to show that this approach to therapy, called switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer. The randomized Phase 2 trial tested this treatment in 108 patients.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
Hunting a full OK for Bavencio in frontline bladder cancer, Pfizer, Merck KGaA receive VIP treatment at FDA [EndPoints] The drug was already sanctioned, under accelerated approval, for use in patients following disease progression — an OK cemented by tumor response and duration of response back in 2017.
	5.2.6 PHARMA - BIOTECH
Tango Therapeutics nabs $60M in CRISPR-based hunt for hidden cancer genes [EndPoints] Tango’s approach is built around a concept called synthetic lethality, the concept that undergirds PARP inhibitors.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
COVID-19, Cancer, and the Need for Clarity [ASH] Despite the presence of 2,170 publications on COVID-19 in a literature search at the time of this writing, there is no data on COVID-19 and the optimal treatment of patients with cancer.
	6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES
Nature to join open-access Plan S, publisher says [Nature] Springer Nature says it commits to offering researchers a route to publishing open access in Nature and most Nature-branded journals from 2021.